Frontlight ResearchEarly access
Gastric and oesophageal cancer trials in France
81 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 15 November 2026. Ask the study team whether a trial fits you.
- Phase 1/2Taking peopleSubstudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
- Where
- Brest, Lille, Paris
- Age
- 18 years and over
- People
- 160 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06469944 · EU 2023-509307-33-00 - Phase 1/2Taking peopleSubstudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
- Where
- Brest, Lille, Paris
- Age
- 18 years and over
- People
- 298 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06780111 · EU 2024-514273-22-00 - No phaseTaking peopleG-POEM for Refractory Gastroparesis After Esophagectomy With Gastric Pull-through
- Where
- Marseille
- Age
- 18 years and over
- People
- 30 worldwide
- Run by
- Institute for Clinical and Experimental Medicine
See details and how to joinNCT06068127 - Phase 3Taking peopleA clinical trial of belzutifan and other treatments in people with solid tumors or von Hippel-Lindau (VHL)-related tumors (MK-6482-043)
- Where
- Angers, Limoges Cedex I, Strasbourg Cedex 2, Toulouse Cedex 9, Villejuif
- Age
- 18 years and over
- People
- 134 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to join2025-524160-38-00 - Phase 1/2Taking peopleA Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
- Where
- Brest, Paris
- Age
- 18 years and over
- People
- 60 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07405151 · EU 2026-525213-31-00 - Phase 1Not yet taking people in FranceA Study of LY4336619 in Adult Participants With Advanced Solid Tumors
- Where
- Lyon, Saint-Herblain, Toulouse, Villejuif
- Age
- 18 years and over
- People
- 370 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07928258 · EU 2026-526553-33-00 - Phase 3Not yet taking people in FranceA Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
- Where
- Bordeaux, Brest, Clermont-Ferrand, Dijon, Grenoble Cedex 9, Lille, Lyon, Lyon Cedex 03, Marseille, Paris, Plérin, Poitiers, Rouen Cedex, Saint-Herblain Cedex, Toulouse Cedex 9, Vandoeuvre Les Nancy_ Cedex, Villejuif
- Age
- 18 years and over
- People
- 570 worldwide
- Run by
- Astellas Pharma Global Development, Inc.
See details and how to joinNCT07673887 · EU 2025-524557-14-00 - No phaseTaking peopleMulticenter Prospective Cohort on Esophageal Endoscopic Submucosal Dissection
- Where
- Bordeaux, Limoges, Lyon, Nancy, Nantes, Rennes, Rouen
- Age
- 18 years and over
- People
- 750
- Run by
- Société Française d'Endoscopie Digestive
See details and how to joinNCT07343869 - Phase 1/2Taking peopleBeamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Where
- Bordeaux, Caen, Lyon, Marseille, Paris, Rennes, Saint-Herblain, Strasbourg, Toulouse, Villejuif
- Age
- 18 years and over
- People
- 910 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT06324357 - Phase 3Active, not recruitingA Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
- Where
- Bordeaux, Brest, Caen Cedex 9, Carcassonne Cedex 9, Dijon, Lille, Lyon, Lyon Cedex 03, Montpellier Cedex 5, Nice Cedex 2, Paris, Plérin, Poitiers, Rouen Cedex, Saint-Herblain Cedex, Strasbourg
- Age
- 18 years and over
- People
- 500 worldwide
- Run by
- Astellas Pharma Global Development, Inc.
See details and how to joinNCT06901531 · EU 2024-519773-19-00 - Phase 2/3Taking peopleA Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
- Where
- Brest, Lille Cedex, Lyon, Marseille, Nantes, Paris, Poitiers
- Age
- 18 years and over
- People
- 690 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07221149 · EU 2025-523263-37-00 - Phase 1Taking peoplePhase 1 Study of PF-08046033 in Advanced Solid Tumors
- Where
- Toulouse, Villejuif
- Age
- 18 years and over
- People
- 250 worldwide
- Run by
- Pfizer
See details and how to joinNCT07519655 - Phase 1SuspendedA Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Where
- Villejuif
- Age
- 18 years and over
- People
- 460 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00 - Phase 2Taking peopleA Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Where
- Bordeaux, Brest, Lille, Montpellier, Pierre-Bénite, Villejuif
- Age
- 18 years and over
- People
- 111 worldwide
- Run by
- Bayer
See details and how to joinNCT06760819 · EU 2024-517419-62-00 - Phase 1Not yet taking people in FranceA Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Where
- Paris, Saint-Herblain
- Age
- 18 years and over
- People
- 421 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07114601 · EU 2025-522367-15-00 - Phase 1/2Taking peopleA Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
- Where
- Bordeaux, Lyon, Marseille, Montpellier Cedex 5, Nice Cedex 2, Paris, Rouen Cedex, Villejuif
- Age
- 18 years and over
- People
- 560 worldwide
- Run by
- Genmab
See details and how to joinNCT03526835 · EU 2024-513627-16-01 - Phase 1/2Taking peopleEIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
- Where
- Pierre-Bénite
- Age
- 18 years and over
- People
- 160 worldwide
- Run by
- Eikon Therapeutics
See details and how to joinNCT07262619 · EU 2026-525248-13-00 - Phase 1/2Taking peopleA Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors
- Where
- Bordeaux, Dijon, Lille, Marseille, Toulouse, Villejuif
- Age
- 18 years and over
- People
- 235 worldwide
- Run by
- Alentis Therapeutics AG
See details and how to joinNCT06747585 · EU 2024-515459-39-00 - Phase 2Taking peopleA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Bordeaux, Dijon, Lille, Lyon, Marseille, Nantes, Toulouse, Vandœuvre-lès-Nancy, Villejuif
- Age
- 18 years and over
- People
- 740 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00 - Phase 1/2Taking peopleA Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Where
- Besancon Cedex, Bordeaux, Bordeaux Cedex, Dijon, Lyon, Montpellier Cedex 5, Paris, Rennes Cedex, Saint-Herblain Cedex, Toulouse Cedex 9, Villejuif
- Age
- 18 years and over
- People
- 680 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00 - Phase 3Taking peopleA Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
- Where
- Avignon, Brest, Dijon, Lille, Lyon, Marseille, Montpellier, Nantes, Nice, Paris, Pessac, Poitiers, Rennes, Saint-Cloud, Strasbourg, Toulouse
- Age
- 18 years and over
- People
- 510 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06644781 · EU 2023-509630-19-00 - Phase 1Not yet taking people in FranceA phase I study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with solid tumors
- Where
- Lyon, Marseille
- Age
- 18 years and over
- People
- 64 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2024-518348-19-00 - No phaseNot yet taking people in FranceBiomarker Investigation for Early Gastric Cancer Detection
- Where
- Lyon
- Age
- 18 years and over
- People
- 100
- Run by
- Centre Leon Berard
See details and how to joinNCT07884669 - Phase 3Taking peopleA Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
- Where
- Bordeaux, Caen Cedex 5, Clermont-Ferrand, Dijon, Lille Cedex, Lyon, Marseille, Poitiers, Rennes Cedex, Strasbourg Cedex 2, Toulouse Cedex 9, Vandoeuvre Les Nancy_ Cedex, Villejuif
- Age
- 18 years and over
- People
- 840 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06764875 · EU 2024-512583-57-00 - Phase 3Taking peopleSonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Where
- Bordeaux, Caen Cedex 5, Lyon, Marseille, Rennes Cedex, Villejuif
- Age
- 18 years and over
- People
- 2,130 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07431281 · EU 2024-519787-40-00